Having failed to find a buyer, Aurinia Pharmaceuticals has resorted to slashing its workforce and R&D pipeline to stay afloat.
Key Takeaways
-
Aurinia’s search for a buyer has drawn a blank – forcing it to downsize it staff and R&D pipeline
The company is now pinning its hopes on building sales of its sole marketed therapy, the lupus nephritis treatment Lupkynis...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?